Relative influence of c‑Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non‑small cell lung cancer

Xiao,Hui; Wang,Juan; Liu,Yanan; Li,Li

doi:10.3892/ol.2014.2173

Relative influence of c‑Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non‑small cell lung cancer

Authors:
- Hui Xiao
- Juan Wang
- Yanan Liu
- Li Li
View Affiliations

Affiliations: Department of Laboratory Medicine, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, P.R. China
Published online on: May 23, 2014 https://doi.org/10.3892/ol.2014.2173
Pages: 582-588

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

c‑Kit and epidermal growth factor receptor (EGFR) have critical roles in cell proliferation and differentiation in patients with non‑small cell lung cancer (NSCLC). The present study aimed to investigate the prognostic impact of c‑Kit and/or EGFR expression in tumor tissue samples from 146 patients with NSCLC. c‑Kit expression was analyzed using immunohistochemistry and the expression of EGFR was assessed using fluorescence in situ hybridization. Univariate and multivariate analyses identified that c‑Kit is a significant negative prognostic factor. The expression of c‑Kit was correlated with poor differentiation, pleura involvement and smoking history (P=0.043, 0.007 and 0.032, respectively). Furthermore, patients with c‑Kit‑positive expression were associated with a significantly lower overall survival compared with those exhibiting c‑Kit‑negative expression (P=0.048). The median follow‑up time was 19 months post‑surgery. EGFR gene amplification as a result of polysomy of chromosome 7 was found to be negatively correlated with poor differentiation and smoking history (P=0.023 and 0.044, respectively). The findings of the present study indicate that c‑Kit and EGFR expression is a strong, independent, negative prognostic factor in NSCLC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
2	American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 171:388–416. 2005.
3	Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–580. 1998.
4	Thiel G, Ekici M and Rössler OG: Regulation of cellular proliferation, differentiation and cell death by activated Raf. Cell Commun Signal. 7:82009.
5	Mirsadraee M, Oswal D, Alizade Y, et al: The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol. 4:128–134. 2012.
6	Lei B, Liu S, Qi W, et al: PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression. Histopathology. 63:696–703. 2013.
7	Erler BS, Presby MM, Finch M, et al: CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma. Tumour Biol. 32:107–111. 2011.
8	Mohammad T, Garratt J, Torlakovic E, Gilks B and Churg A: Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice. Am J Surg Pathol. 36:1503–1508. 2012.
9	Cheng D, Kong H and Li Y: Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer. Biomarkers. 18:386–390. 2013.
10	Chatterjee S, Heukamp LC, Siobal M, et al: Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 123:1732–1740. 2013.
11	Yang Y, Li J, Mao S and Zhu H: Comparison of immunohistology using pan-CK and EMA in the diagnosis of lymph node metastasis of gastric cancer, particularly micrometastasis and isolated tumor cells. Oncol Lett. 5:768–772. 2013.
12	Kanapathy Pillai SK, Tay A, Nair S and Leong CO: Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol. 12:182012.
13	Al-Dubai SA, Qureshi AM, Saif-Ali R, Ganasegeran K, Alwan MR and Hadi JI: Awareness and knowledge of breast cancer and mammography among a group of Malaysian women in Shah Alam. Asian Pac J Cancer Prev. 12:2531–2538. 2011.
14	Casali C, Stefani A, Rossi G, et al: The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 77:247–253. 2004.
15	Boldrini L, Ursino S, Gisfredi S, et al: Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res. 10:4101–4108. 2004.
16	López-Martin A, Ballestín C, Garcia-Carbonero R, et al: Prognostic value of KIT expression in small cell lung cancer. Lung Cancer. 56:405–413. 2007.
17	Yoo J, Kim CH, Song SH, et al: Expression of c-kit and p53 in non-small cell lung cancers. Cancer Res Treat. 36:167–172. 2004.
18	Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 353:133–144. 2005.
19	Hirsch FR, Herbst RS, Olsen C, et al: Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 26:3351–3357. 2008.
20	Park EA, Lee HJ, Kim YT, et al: EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology. Lung Cancer. 64:179–186. 2009.
21	Dy GK, Miller AA, Mandrekar SJ, et al: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 16:1811–1816. 2005.
22	Schneider BJ, Kalemkerian GP, Ramnath N, et al: Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer. 11:223–227. 2010.